Vir’s GSK-allied flu prevention antibody fails PhII, sinking shares and late-stage hope

Vir Biotechnology’s influenza antibody has failed a critical Phase II clinical trial, which could spell bad news for its partner GSK, who has the option to take over development of VIR-2482.

A flop on the mid-stage PENINSULA trial, funded in part by a $55 million boost from the federal government,…
Click here to view original post

Advertisement — Advertise with Biotech Networks